Biaxin XL Related Published Studies
Well-designed clinical trials related to Biaxin XL (Clarithromycin)
Expression comparison of azithromycin and clarithromycin in triple-therapy
regimens for eradication of Helicobacter pylori in hemodialysis patients. [2014]
Evaluation of subgingivally delivered 0.5% clarithromycin as an adjunct to
nonsurgical mechanotherapy in the management of chronic periodontitis: a
short-term double blinded randomized control trial. [2014]
Cethromycin versus clarithromycin for community-acquired pneumonia: comparative
efficacy and safety outcomes from two double-blinded, randomized, parallel-group,
multicenter, multinational noninferiority studies. [2012]
Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled
trial. [2012]
Clarithromycin, as an adjunct to non surgical periodontal therapy for chronic periodontitis: a double blinded, placebo controlled, randomized clinical trial. [2011.10]
A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. [2011.09.18]
Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. [2011.06]
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. [2011.03.12]
A randomised controlled trial assessing the effect of adding clarithromycin to rifampicin, ofloxacin and minocycline in the treatment of single lesion paucibacillary leprosy in Agra District, India. [2011.03]
Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients. [2011.02]
Bioequivalence study of two oral formulations of clarithromycin in human male subjects. [2011.01]
Clarithromycin, as an adjunct to non surgical periodontal therapy for chronic
periodontitis: a double blinded, placebo controlled, randomized clinical trial. [2011]
Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. [2010.12]
The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. [2010.12]
Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. [2010.11]
A trial of clarithromycin for the treatment of suboptimally controlled asthma. [2010.10]
Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. [2010.09]
Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. [2010.08]
Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. [2010.07]
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. [2010.05]
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. [2010.05]
A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection. [2010.04]
Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. [2010.02]
Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? [2009.12]
Beneficial effect of clarithromycin in patients with acute coronary syndrome and complement C4 deficiencies. [2009.12]
Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status. [2009.09]
Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. [2009.08]
Efficacy of the standard quadruple therapy versus triple therapies containing proton pump inhibitor plus amoxicillin and clarithromycin or amoxicillin-clavulanic acid and metronidazole for Helicobacter pylori eradication in children. [2009.08]
Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. [2009.07]
Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. [2009.06]
A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for Helicobacter pylori eradication in a developing country. [2009.04]
Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure. [2009.04]
A PK/PD approach on the effects of clarithromycin against oral and nasal microbiota of healthy volunteers. [2009.02]
Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study. [2009]
Pharmacokinetics and comparative bioavailability study of two clarithromycin suspensions following administration of a single oral dose to healthy volunteers. [2009]
Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. [2008.12]
Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. [2008.12]
Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers. [2008.11]
Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers. [2008.10]
Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. [2008.07]
Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. [2008.06]
Prevalence of A2143G mutation of H. pylori-23S rRNA in Chinese subjects with and without clarithromycin use history. [2008.05.28]
Clarithromycin for 2 Weeks for Stable Coronary Heart Disease: 6-Year Follow-Up of the CLARICOR Randomized Trial and Updated Meta-Analysis of Antibiotics for Coronary Heart Disease. [2008.05.02]
Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. [2008.01]
Clarithromycin for 2 Weeks for Stable Coronary Heart Disease: 6-Year Follow-Up of the CLARICOR Randomized Trial and Updated Meta-Analysis of Antibiotics for Coronary Heart Disease. [2008]
No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects. [2008]
An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. [2007.07]
Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. [2007.06]
Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. [2007.06]
Effects of clarithromycin in patients with active rheumatoid arthritis. [2007.03]
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. [2007.02.10]
Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. [2007.02]
Clarithromycin in the treatment of RSV bronchiolitis: A double-blind, randomized, placebo-controlled trial. [2006.10.18]
Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial. [2006.10]
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. [2006.10]
Comparative study of modified-release clarithromycin and immediate-release clarithromycin in the treatment of Helicobacter pylori-associated peptic ulcer disease. [2006.09]
Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. [2006.08]
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. [2006.07.15]
Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. [2006.07.01]
Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. [2006.04]
Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. [2006.03]
Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A Activity: Comparison of a Milk Thistle and Black Cohosh Product to Rifampin and Clarithromycin. [2006.02]
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. [2006.01.17]
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. [2006.01.07]
Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease. [2006.01]
Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high- and low-dose clarithromycin in Japanese patients: a randomised, double-blind, multicentre study. [2006]
[Efficacy and safety of extended-release clarithromycin (5-day short-course) vs telithromycin, in acute bacterial exacerbation of chronic bronchitis] [2005.10]
Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. [2005.10]
Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization. [2005.10]
Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. [2005.09]
Comparative bioavailability of clarithromycin formulations in healthy brazilian volunteers. [2005.08]
One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer. [2005.06.21]
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. [2005.06]
Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. [2005.04.28]
Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. [2005.03.21]
Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. [2005.03]
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. [2005.03]
Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial. [2005.03]
Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. [2005.02.01]
The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. [2005.02]
Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. [2005.02]
Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study. [2005.01]
Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. [2005]
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. [2004.12]
The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). [2004.12]
Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. [2004.12]
Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. [2004.11]
The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). [2004.10]
Clarithromycin suspension: bioequivalence studies on two different strengths. [2004.09]
Two dosages of clarithromycin for five days, amoxicillin/clavulanate for five days or penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. [2004.09]
[The effects of clarithromycin treatment on cardiac events in acute coronary syndrome patients] [2004.09]
The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. [2004.09]
Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. [2004.08]
Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. [2004.07.31]
Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. [2004.07]
Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. [2004.05]
Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. [2004.05]
Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. [2004.05]
Quality of life in treatment of acute rhinosinusitis with clarithromycin and amoxicillin/clavulanate. [2004.05]
A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia. [2004.05]
Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. [2004.05]
|
